Aligos Therapeutics

$22.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.87 (+4.04%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ALGS and other stocks, options, and ETFs commission-free!

About ALGS

Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA. The listed name for ALGS is Aligos Therapeutics, Inc. Common Stock.

CEO
Lawrence M. Blatt
Employees
61
Headquarters
South San Francisco, California
Founded
2018
Market Cap
957.33M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
70.60K
High Today
$22.47
Low Today
$20.00
Open Price
$21.47
Volume
53.88K
52 Week High
$37.51
52 Week Low
$12.82

ALGS Earnings

-$11.00
-$7.33
-$3.67
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 19, Pre-Market

You May Also Like

ATAC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure